| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The target of GalNac-L96 analog is the asialoglycoprotein receptor (ASGPR), a C-type lectin receptor highly expressed on hepatocytes. The final ligand GalNAc-L96 is designed to bind ASGPR with high affinity, enabling receptor-mediated endocytosis for targeted delivery of therapeutic payloads to the liver.
|
|---|---|
| ln Vitro |
In vitro, GalNac-L96 analog is used as a synthetic intermediate rather than as an active biological agent. Its activity is assessed by its ability to serve as a precursor for the synthesis of the ASGPR ligand GalNAc-L96. The final ligand shows high-affinity binding to ASGPR-expressing cells, enabling targeted delivery.
|
| ln Vivo |
In vivo, the GalNac-L96 analog itself is not the active agent; rather, it is the precursor to GalNAc-L96, which is used for targeted delivery to hepatocytes via ASGPR-mediated endocytosis. This targeting strategy is widely used in oligonucleotide therapeutics for liver-specific delivery, as exemplified by FDA-approved drugs that utilize similar GalNAc conjugation technology.
|
| Enzyme Assay |
The non-cellular assay for GalNac-L96 analog involves its use as a chemical intermediate in organic synthesis. The compound is characterized by standard analytical techniques including HPLC, NMR, and mass spectrometry to confirm its identity and purity. Its suitability as a precursor is assessed by its ability to undergo the required chemical transformations to yield the final ASGPR ligand GalNAc-L96.
|
| Cell Assay |
In vitro cell-based assays for the GalNac-L96 analog are not typically performed, as it is a synthetic intermediate rather than a biologically active compound. However, the final GalNAc-L96 ligand can be evaluated for ASGPR binding using hepatocyte cell lines (e.g., HepG2 cells) in binding and uptake assays to confirm receptor-mediated endocytosis.
|
| Animal Protocol |
In vivo animal study protocols for GalNac-L96 analog are not applicable, as it is a synthetic intermediate. The final GalNAc-L96 ligand, however, can be studied in animal models to evaluate ASGPR-mediated liver targeting. Standard protocols involve administering the ligand conjugated to therapeutic payloads and assessing liver uptake, biodistribution, and efficacy in disease models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of GalNac-L96 analog are not characterized, as it is a synthetic intermediate rather than a therapeutic agent. The final GalNAc-L96 ligand, when conjugated to therapeutic payloads, exhibits favorable PK properties including extended circulation half-life and efficient liver targeting via ASGPR-mediated uptake.
|
| Toxicity/Toxicokinetics |
Toxicological data for GalNac-L96 analog are not reported, as it is a synthetic intermediate for research use. The final GalNAc-L96 ligand, when used in therapeutic conjugates, would be subject to standard toxicological evaluation. The ASGPR targeting approach is generally considered safe and has been validated in multiple FDA-approved therapies.
|
| Additional Infomation |
GalNac-L96 analog (CAS# 1159408-72-6) is a research compound used as an intermediate in the synthesis of ASGPR ligands. Its molecular formula is C117H175N11O42 with a molecular weight of 2407.69. It is classified under LYTACs (Lysosome-Targeting Chimeras) pathway. The compound is not a therapeutic drug and has no clinical trial or marketing authorization status.
|
| Molecular Formula |
C117H175N11O42
|
|---|---|
| Molecular Weight |
2407.69
|
| Exact Mass |
2407.193
|
| CAS # |
1159408-72-6
|
| PubChem CID |
162394060
|
| Appearance |
Typically exists as solids at room temperature
|
| Density |
1.29±0.1 g/cm3(Predicted)
|
| Boiling Point |
1849.6±65.0 °C(Predicted)
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
42
|
| Rotatable Bond Count |
89
|
| Heavy Atom Count |
170
|
| Complexity |
4480
|
| Defined Atom Stereocenter Count |
17
|
| SMILES |
C(C1C=CC=CC=1)(C1C=CC(OC)=CC=1)(C1C=CC(OC)=CC=1)OC[C@@H]1C[C@@H](O)CN1C(=O)CCCCCCCCCCC(=O)NC(COCCC(=O)NCCCNC(=O)CCCCO[C@@H]1O[C@H](COC(=O)C)[C@H](OC(=O)C)[C@H](OC(=O)C)[C@H]1NC(=O)C)(COCCC(=O)NCCCNC(=O)CCCCO[C@@H]1O[C@H](COC(=O)C)[C@H](OC(=O)C)[C@H](OC(=O)C)[C@H]1NC(=O)C)COCCC(=O)NCCCNC(=O)CCCCO[C@@H]1O[C@H](COC(=O)C)[C@H](OC(=O)C)[C@H](OC(=O)C)[C@H]1NC(=O)C
|
| InChi Key |
GGDUVQWHSIEKKC-LJNDWZPRSA-N
|
| InChi Code |
InChI=1S/C117H175N11O42/c1-74(129)124-104-110(165-83(10)138)107(162-80(7)135)93(68-158-77(4)132)168-113(104)155-59-29-26-37-96(142)118-53-32-56-121-99(145)50-62-152-71-116(72-153-63-51-100(146)122-57-33-54-119-97(143)38-27-30-60-156-114-105(125-75(2)130)111(166-84(11)139)108(163-81(8)136)94(169-114)69-159-78(5)133,73-154-64-52-101(147)123-58-34-55-120-98(144)39-28-31-61-157-115-106(126-76(3)131)112(167-85(12)140)109(164-82(9)137)95(170-115)70-160-79(6)134)127-102(148)40-24-19-17-15-16-18-20-25-41-103(149)128-66-90(141)65-89(128)67-161-117(86-35-22-21-23-36-86,87-42-46-91(150-13)47-43-87)88-44-48-92(151-14)49-45-88/h21-23,35-36,42-49,89-90,93-95,104-115,141H,15-20,24-34,37-41,50-73H2,1-14H3,(H,118,142)(H,119,143)(H,120,144)(H,121,145)(H,122,146)(H,123,147)(H,124,129)(H,125,130)(H,126,131)(H,127,148)/t89-,90+,93+,94+,95+,104+,105+,106+,107-,108-,109-,110+,111+,112+,113+,114+,115+/m0/s1
|
| Chemical Name |
[(2R,3R,4R,5R,6R)-5-acetamido-6-[5-[3-[3-[3-[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-diacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-diacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]-2-[[12-[(2S,4R)-2-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-4-hydroxypyrrolidin-1-yl]-12-oxododecanoyl]amino]propoxy]propanoylamino]propylamino]-5-oxopentoxy]-3,4-diacetyloxyoxan-2-yl]methyl acetate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.4153 mL | 2.0767 mL | 4.1534 mL | |
| 5 mM | 0.0831 mL | 0.4153 mL | 0.8307 mL | |
| 10 mM | 0.0415 mL | 0.2077 mL | 0.4153 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
